Lipoprotein(a) in familial hypercholesterolemia

20260 citationsJournal Article

Authors

Abstract

It is highly recommended to systematically measure Lp(a) in FH patients. These patients should be treated with high-dose statins, when necessary, in combination with a proprotein convertase subtilisin/kexin type 9 inhibitor to reach LDL-C therapeutic goals. Hopefully, the Lp(a) lowering therapies currently under development will prove instrumental for adequate treatment of FH patients with concomitantly elevated Lp(a) in coming years.

Topics & Keywords

Lipoproteins and Cardiovascular Health HIV-related health complications and treatments Atherosclerosis and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Current Opinion in Lipidology

DOI: 10.1097/mol.0000000000001032

Field-Weighted Citation Impact: 0.00